AstraZeneca shares topple after drug blow

Pharmaceuticals giant AstraZeneca saw its share price fall sharply today after it emerged that a key drug in its portfolio did not boost the survival chances of some patients.

AstraZeneca said the trial of 1,700 lung cancer sufferers showed the treatment Iressa, which is not available in the UK, shrank tumours but not to an extent that significantly prolonged life.